Literature DB >> 16633057

Rifaximin for active ulcerative colitis.

Mario Guslandi, Maria Chiara Petrone, Pier Alberto Testoni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16633057     DOI： 10.1097/01.MIB.0000215092.85116.6c

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  14 in total

1.  Rifaximin for inflammatory bowel disease.

Authors:  Mario Guslandi
Journal:  Dig Dis Sci       Date:  2010-06       Impact factor: 3.199

2.  Targeting intestinal microflora in inflammatory bowel disease.

Authors:  Mario Guslandi
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

Review 3.  The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease.

Authors:  Julia B Ewaschuk; Qassim Z Tejpar; Isaac Soo; Karen Madsen; Richard N Fedorak
Journal:  Curr Gastroenterol Rep       Date:  2006-12

4.  Rifaximin in the treatment of inflammatory bowel disease.

Authors:  Mario Guslandi
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

Review 5.  Microbial translocation across the GI tract.

Authors:  Jason M Brenchley; Daniel C Douek
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

Review 6.  Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Authors:  Hoonmo L Koo; Herbert L DuPont
Journal:  Curr Opin Gastroenterol       Date:  2010-01       Impact factor: 3.287

Review 7.  The pregnane X receptor: from bench to bedside.

Authors:  Xiaochao Ma; Jeffrey R Idle; Frank J Gonzalez
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-07       Impact factor: 4.481

Review 8.  Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis.

Authors:  Matthew J Bull; Nigel T Plummer
Journal:  Integr Med (Encinitas)       Date:  2015-02

Review 9.  Use of rifaximin in gastrointestinal and liver diseases.

Authors:  Rani H Shayto; Rachel Abou Mrad; Ala I Sharara
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 10.  Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.

Authors:  Francesca Romana Ponziani; Viviana Gerardi; Silvia Pecere; Francesca D'Aversa; Loris Lopetuso; Maria Assunta Zocco; Maurizio Pompili; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.